scholarly journals Protective and Therapeutic Capacity of Human Single-Chain Fv-Fc Fusion Proteins against West Nile Virus

2005 ◽  
Vol 79 (23) ◽  
pp. 14606-14613 ◽  
Author(s):  
L. Hannah Gould ◽  
Jianhua Sui ◽  
Harald Foellmer ◽  
Theodore Oliphant ◽  
Tian Wang ◽  
...  
Keyword(s):  
West Nile Virus ◽  
Virus Infection ◽  
Envelope Protein ◽  
Fusion Proteins ◽  
Passive Immunization ◽  
West Nile Virus Infection ◽  
The United States ◽  
Single Chain ◽  
West Nile ◽  
Virus Serotype

ABSTRACT West Nile virus has spread rapidly across the United States, and there is currently no approved human vaccine or therapy to prevent or treat disease. Passive immunization with antibodies against the envelope protein represents a promising means to provide short-term prophylaxis and treatment for West Nile virus infection. In this study, we identified a panel of 11 unique human single-chain variable region antibody fragments (scFvs) that bind the envelope protein of West Nile virus. Selected scFvs were converted to Fc fusion proteins (scFv-Fcs) and were tested in mice for their ability to prevent lethal West Nile virus infection. Five of these scFv-Fcs, 11, 15, 71, 85, and 95, protected 100% of mice from death when given prior to infection with virus. Two of them, 11 and 15, protected 80% of mice when given at days 1 and 4 after infection. In addition, four of the scFv-Fcs cross-neutralized dengue virus, serotype 2. Binding assays using yeast surface display demonstrated that all of our scFvs bind to sites within domains I and II of West Nile virus envelope protein. These recombinant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus infections.

scholarly journals Human Monoclonal Antibodies against NS1 Protein Protect against Lethal West Nile Virus Infection

mBio ◽  
2021 ◽  
Author(s):  
Alex W. Wessel ◽  
Michael P. Doyle ◽  
Taylor B. Engdahl ◽  
Jessica Rodriguez ◽  
James E. Crowe ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
West Nile Virus ◽  
Virus Infection ◽  
Envelope Protein ◽  
West Nile Virus Infection ◽  
Therapeutic Antibodies ◽  
Ns1 Protein ◽  
Human Monoclonal Antibodies ◽  
West Nile ◽  
Paradoxical Worsening

Therapeutic antibodies against flaviviruses often promote neutralization by targeting the envelope protein of the virion. However, this approach is hindered by a possible concern for antibody-dependent enhancement of infection and paradoxical worsening of disease.

scholarly journals Up-to-date knowledge of West Nile virus infection

2009 ◽  
Vol 62 (5-6) ◽  
pp. 231-235
Author(s):  
Ivana Hrnjakovic-Cvjetkovic ◽  
Dejan Cvjetkovic ◽  
Dusan Petric ◽  
Vesna Milosevic ◽  
Vera Jerant-Patic ◽  
...  
Keyword(s):  
West Nile Virus ◽  
Virus Infection ◽  
Mosquito Control ◽  
Virus Disease ◽  
West Nile Virus Infection ◽  
The United States ◽  
Flaccid Paralysis ◽  
Adult Mosquito ◽  
West Nile Fever ◽  
West Nile

Virus West Nile virus is a single-stranded RNA virus of the family Flaviviridae, genus Flavivirus. Epidemiology West Nile virus is maintained in the cycle involving culicine mosquitoes and birds .Humans typically acquire West Nile infection through a bite from infected adult mosquito. Person to person transmission can occur through organ transplantation, blood and blood product transfusions, transplacentally and via brest milk. Human cases of West Nile infections were recorded in Africa, Israel, Russia, India, Pakistan. In Romania in 1996 West Nile fever occurred with hundreds of neurologic cases and 17 fatalities. First human cases in the United States were in New York City where 59 persons were infected and had fever, meningitis, encephalitis and flaccid paralysis. Clinical manifestation Most human cases are asymptomatic. The majority of symptomatic patients have a self limited febrile illness. Fatigue, nausea, vomiting, eye pain, headache, myalgias, artralgias, lymphadenopathy and rash are common complaints. Less than 1% of all infected persons develop more severe neurologic illness including meningitis, encefalitis and flaccid paralysis. Laboratory diagnosis Diagnosis of West Nile virus infection is based on serologic testing, isolation of virus from patient samples and detection of viral antigen or viral genom. ELISA test and indirect immunofluorescenceassay are used for detecting IgM and IgG antibodies in serum and cerebrospinal fluid. Treatment In vitro studies have suggested that ribavirin and interferon alfa -2b may be useful in the treatment of West Nile virus disease. Prevention The most important measures are mosquito control program and personal protective measures. .

Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice

Vaccine ◽  
2014 ◽  
Vol 32 (7) ◽  
pp. 800-808 ◽  
Author(s):  
Sofia E. Magnusson ◽  
Karin H. Karlsson ◽  
Jenny M. Reimer ◽  
Silke Corbach-Söhle ◽  
Sameera Patel ◽  
...  
Keyword(s):  
West Nile Virus ◽  
Virus Infection ◽  
Envelope Protein ◽  
West Nile Virus Infection ◽  
Protein Vaccine ◽  
West Nile

scholarly journals Single-Chain HLA-A2 MHC Trimers That Incorporate an Immundominant Peptide Elicit Protective T Cell Immunity against Lethal West Nile Virus Infection

2010 ◽  
Vol 184 (8) ◽  
pp. 4423-4430 ◽  
Author(s):  
Sojung Kim ◽  
Lijin Li ◽  
Curtis P. McMurtrey ◽  
William H. Hildebrand ◽  
Jon A. Weidanz ◽  
...  
Keyword(s):  
West Nile Virus ◽  
T Cell ◽  
Virus Infection ◽  
West Nile Virus Infection ◽  
T Cell Immunity ◽  
Single Chain ◽  
West Nile ◽  
Cell Immunity

scholarly journals Transfusion associated West Nile virus infection: implications for Europe

2003 ◽  
Vol 7 (34) ◽  
Author(s):  
R Brown ◽  
N Crowcroft ◽  
D Morgan ◽  
R Eglin
Keyword(s):  
United States ◽  
West Nile Virus ◽  
North America ◽  
Virus Infection ◽  
West Nile Virus Infection ◽  
The United States ◽  
West Nile ◽  
Human West Nile Virus

There was a large increase in reported numbers of human West Nile virus infection in North America in 2002, compared with previous years, with 4156 cases identified in the United States

scholarly journals Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Stefan Chabierski ◽  
Luisa Barzon ◽  
Anna Papa ◽  
Matthias Niedrig ◽  
Jonathan L Bramson ◽  
...  
Keyword(s):  
West Nile Virus ◽  
Virus Infection ◽  
Envelope Protein ◽  
West Nile Virus Infection ◽  
West Nile ◽  
Fusion Loop ◽  
Recombinant Envelope Protein
Sign in / Sign up

Export Citation Format

Share Document